Clinical Trial Update: An Extension Study to Assess Long-term Safety, Tolerability, and Efficacy of KarXT in Adult Patients With Schizophrenia (EMERGENT-4) [Phase 3]

View source ↗

Summary

Extension study EMERGENT-4 evaluated long-term safety, tolerability, and efficacy of KarXT in adults with schizophrenia; results from this Phase 3 trial have be…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• KarXT (xanomeline-trospium)

Snippet

Sponsor: Karuna Therapeutics, Inc., a Bristol Myers Squibb company | Conditions: Schizophrenia | Phase 3 | Status: COMPLETED | Results posted: 2024-10-28